Oral Piracetam vs Betahistine in Outpatient Management of Peripheral Vertigo; a Randomized Clinical Trial
Archives of Academic Emergency Medicine,
Vol. 7 No. 1 (2019),
1 January 2019
,
Page e9
https://doi.org/10.22037/aaem.v7i1.288
Abstract
Introduction: Although vertigo is a common complaint in patients presenting to the emergency department (ED), its ideal treatment is still under debate. This study was conducted to compare oral betahistine and oral piracetam in management of outpatients with peripheral vertigo.
Methods: This was a randomized clinical trial performed on patients who were presented to the EDs of 4 teaching hospitals, with complaint of true vertigo. Patients were randomly allocated to either betahistine or piracetam group and their 7-day outcomes were compared.
Results: 100 cases with the mean age of 54.72 ± 14.09 years were randomly allocated to either group (62.0% female). The two groups were similar regarding age, sex, and intensity of symptom at the time of presenting to the ED. Twelve (24%) patients in piracetam group and 6 (12%) patients in betahistine group experienced adverse events (odds ratio: 2.32, CI 95%: 0.79-6.76; p = 0.125). There were 3 (6%) patients in each group that experienced a recurrence of their symptoms and 2 (4%) patients in each group saw another physician for vertigo.
Conclusion: Oral piracetam is a potentially proper treatment for management of peripheral vertigo and there are few adverse effects associated with it.
- Vertigo
- piracetam
- betahistine
- emergency medicine
- treatment outcome
How to Cite
References
Omron R. Peripheral Vertigo. Emerg Med Clin North Am. 2019;37(1):11-28.
Spiegel R, Kirsch M, Rosin C, Rust H, Baumann T, Sutter R, et al. Dizziness in the emergency department: an update on diagnosis. Swiss Med Wkly. 2017;147:w14565.
Shahrami A, Norouzi M, Kariman H, Hatamabadi HR, Arhami Dolatabadi A. True Vertigo Patients in Emergency Department; an Epidemiologic Study. 2016. 2016;4(1):4.
Spiegel R, Rust H, Baumann T, Friedrich H, Sutter R, Goldlin M, et al. Treatment of dizziness: an interdisciplinary update. Swiss Med Wkly. 2017;147:w14566.
Akdoğan Ö, HN. A, S. B. Kronik vertigolu hastalarda oral pirasetam kullanımı. . Turk Arch Otolaryngol. 2003(41):139-45.
Dogan NO, Avcu N, Yaka E, Yilmaz S, Pekdemir M. Comparison of the therapeutic efficacy of intravenous dimenhydrinate and intravenous piracetam in patients with vertigo: a randomised clinical trial. Emerg Med J. 2015;32(7):520-4.
Melnikov OA, Lilenko SV, Nauta J, Ouwens MJ. Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD study. Curr Med Res Opin. 2015;31(11):1951-62.
Oosterveld WJ. The effectiveness of piracetam in vertigo. Pharmacopsychiatry. 1999;32 Suppl 1:54-60.
Ozdemir H, Akinci E, Coskun F. Comparison of the effectiveness of intravenous piracetam and intravenous dimenhydrinate in the treatment of acute peripheral vertigo in the emergency department. Singapore Med J. 2013;54(11):649-52.
Rosenhall U, Deberdt W, Friberg U, Kerr A, Oosterveld W. Piracetam in patients with chronic vertigo. Clinical drug investigation. 1996;11(5):251-60.
Melnikov OA, Lilenko SV, Nauta J, Ouwens MJ. Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD study. Current medical research and opinion. 2015;31(11):1951-62.
Doğan NÖ, Avcu N, Yaka E, Yılmaz S, Pekdemir M. Comparison of the therapeutic efficacy of intravenous dimenhydrinate and intravenous piracetam in patients with vertigo: a randomised clinical trial. Emerg Med J. 2015;32(7):520-4.
Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. Cochrane Database Syst Rev. 2016(6):CD010696.
Ramos Alcocer R, Ledezma Rodriguez JG, Navas Romero A, Cardenas Nunez JL, Rodriguez Montoya V, Deschamps JJ, et al. Use of betahistine in the treatment of peripheral vertigo. Acta Otolaryngol. 2015;135(12):1205-11.
Strupp M, Zwergal A, Feil K, Bremova T, Brandt T. Pharmacotherapy of vestibular and cerebellar disorders and downbeat nystagmus: translational and back-translational research. Ann N Y Acad Sci. 2015;1343:27-36.
Dziadziola JK, Laurikainen EL, Rachel JD, Quirk WS. Betahistine increases vestibular blood flow. Otolaryngol Head Neck Surg. 1999;120(3):400-5.
Lacour M. Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. J Vestib Res. 2013;23(3):139-51.
Albu S, Chirtes F, Trombitas V, Nagy A, Marceanu L, Babighian G, et al. Intratympanic dexamethasone versus high dosage of betahistine in the treatment of intractable unilateral Meniere disease. Am J Otolaryngol. 2015;36(2):205-9.
Chavez H, Vega R, Soto E. Histamine (H3) receptors modulate the excitatory amino acid receptor response of the vestibular afferents. Brain Res. 2005;1064(1-2):1-9.
Djelilovic-Vranic J, Alajbegovic A, Tiric-Campara M, Volic A, Sarajlic Z, Osmanagic E, et al. Betahistine or Cinnarizine for treatment of Meniere's disease. Med Arch. 2012;66(6):396-8.
Jeck-Thole S, Wagner W. Betahistine: a retrospective synopsis of safety data. Drug Saf. 2006;29(11):1049-59.
Lacour M, van de Heyning PH, Novotny M, Tighilet B. Betahistine in the treatment of Meniere's disease. Neuropsychiatr Dis Treat. 2007;3(4):429-40.
Ince Gunal D, Agan K, Afsar N, Borucu D, Us O. The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients. J Clin Pharm Ther. 2008;33(2):175-8.
Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169-82.
Winnicka K, Tomasiak M, Bielawska A. Piracetam--an old drug with novel properties? Acta Pol Pharm. 2005;62(5):405-9.
- Abstract Viewed: 618 times
- PDF Downloaded: 426 times
- HTML Downloaded: 129 times